top of page


European Commission approves Revolution Medicines' Rasonque as first broad RAS-targeted therapy for metastatic pancreatic cancer
The European Commission has authorised Revolution Medicines' Rasonque as an oral broad RAS-targeted treatment for previously treated metastatic pancreatic cancer, marking a significant advance in a disease with substantial unmet medical need.

nuaxia
6 hours ago2 min read


OBI Pharma signs ADC platform licensing agreement with Novartis worth more than $2 billion
OBI Pharma has entered a global antibody-drug conjugate platform licensing agreement with Novartis carrying more than $2 billion in potential value, including a $30 million upfront payment and additional contingent milestones and royalties.

nuaxia
1 day ago2 min read


CHMP recommends Innovent's Zybrivo sintilimab for first-line non-squamous lung cancer in Europe
The EMA's CHMP has recommended Innovent's Zybrivo, containing sintilimab, for first-line treatment of eligible patients with non-squamous non-small cell lung cancer, advancing the immunotherapy towards a potential European marketing authorisation.

nuaxia
1 day ago2 min read


FDA approves Biocon's Pebrilzo pertuzumab biosimilar for HER2-positive breast cancer
Biocon has secured US FDA approval for Pebrilzo, a pertuzumab biosimilar for HER2-positive breast cancer, expanding its oncology biosimilar portfolio while commercial entry remains subject to a patent settlement allowing launch from the third quarter of 2028.

nuaxia
1 day ago2 min read


FDA declines approval of Summit and Akeso's ivonescimab for EGFR-mutated lung cancer
The FDA has issued a Complete Response Letter for Summit Therapeutics' ivonescimab in EGFR-mutated lung cancer after the HARMONi trial demonstrated a progression-free survival benefit but did not establish a statistically significant overall-survival benefit.

nuaxia
1 day ago2 min read


UK MHRA approves Incyte's Zynyz for advanced anal cancer as NICE backs NHS access
The UK MHRA has authorised Incyte's Zynyz with carboplatin and paclitaxel for advanced anal cancer, accompanied by a positive NICE access recommendation and Phase III evidence of improved median overall survival.

nuaxia
4 days ago2 min read


European Commission expands Oncopeptides' Pepaxti authorisation to third-line multiple myeloma
The European Commission has approved an expansion of Oncopeptides' Pepaxti label into third-line multiple myeloma treatment, broadening eligibility after two prior lines of therapy and removing the previous triple-class refractory requirement.

nuaxia
4 days ago2 min read


NICE backs Padcev and Keytruda combination around surgery for muscle-invasive bladder cancer
NICE has issued positive final draft guidance for perioperative Padcev and Keytruda in muscle-invasive bladder cancer, potentially expanding NHS treatment access before and after surgery for eligible patients regardless of cisplatin suitability.

nuaxia
5 days ago2 min read


FDA approves Merck KGaA's Pimjetmi for symptomatic tenosynovial giant cell tumour
Merck KGaA's oral CSF1R inhibitor Pimjetmi has received FDA approval for adults with symptomatic tenosynovial giant cell tumour when surgery could cause substantial functional impairment, supported by a 56% response rate in the Phase III MANEUVER trial.

nuaxia
6 days ago2 min read


Brazil approves Henlius and Organon's pertuzumab biosimilar for HER2-positive breast cancer
Brazil's health regulator has approved Henlius and Organon's pertuzumab biosimilar for certain HER2-positive breast cancer patients, marking the country's first authorisation of a biosimilar to this established oncology antibody.

nuaxia
Nov 102 min read


ImmunityBio begins European patient treatment with Anktiva plus BCG for bladder cancer
ImmunityBio has begun treating patients in Europe with Anktiva plus BCG for a defined form of BCG-unresponsive bladder cancer, marking an early commercial-access milestone following its existing European authorisation.

nuaxia
Nov 62 min read


FDA grants accelerated approval to Johnson & Johnson's Rybrevant Faspro for advanced head and neck cancer
Johnson & Johnson's subcutaneous EGFR/MET-targeted therapy has received FDA accelerated approval for a defined population of adults with previously treated recurrent or metastatic head and neck squamous cell carcinoma.

nuaxia
Nov 62 min read


Karyopharm plans Ayrmid merger through Chapter 11 restructuring with $55 million financing commitment
Karyopharm Therapeutics has announced a proposed merger with Ayrmid through a court-supervised Chapter 11 restructuring process, supported by a $55 million additional financing commitment.

nuaxia
Nov 52 min read


Boehringer Ingelheim signs Sino Biopharmaceutical oncology deal worth up to $7.36 billion
Boehringer Ingelheim has entered a major oncology partnership with Sino Biopharmaceutical covering six preclinical antibody-drug conjugate and T-cell engager programmes, with potential payments reaching approximately $7.36 billion.

nuaxia
Nov 52 min read


European Commission approves Enhertu for residual HER2-positive early breast cancer after neoadjuvant therapy
The European Commission has approved Enhertu for patients with residual HER2-positive early breast cancer, extending the antibody-drug conjugate into a curative-intent treatment setting.

nuaxia
Nov 22 min read


FDA approves Talzenna plus Xtandi for HRR-mutated metastatic hormone-sensitive prostate cancer
The FDA has approved Pfizer's Talzenna plus Xtandi for HRR-mutated metastatic hormone-sensitive prostate cancer, expanding the combination into an earlier treatment setting.

nuaxia
Oct 272 min read


European Commission approves Tecvayli monotherapy from first relapse in multiple myeloma
The European Commission has approved Johnson & Johnson's Tecvayli monotherapy from first relapse in multiple myeloma, moving the bispecific antibody into an earlier treatment setting.

nuaxia
Oct 272 min read


FDA grants full approval to Keytruda and Keytruda Qlex for TMB-high advanced solid tumours with updated biomarker threshold
The FDA has converted Keytruda's tumour-mutational-burden-high solid tumour indication to traditional approval, extending the authorisation to Keytruda Qlex and updating the biomarker threshold.

nuaxia
Oct 232 min read


Menarini Stemline licenses Georgiamune GIM-621 oral cancer immunotherapy in deal worth up to $1.1 billion
Menarini's Stemline Therapeutics has secured worldwide rights to Georgiamune's investigational oral cancer immunotherapy GIM-621 in a licensing agreement worth up to $1.1 billion.

nuaxia
Oct 232 min read


European Commission approves Keytruda plus Padcev for perioperative treatment of muscle-invasive bladder cancer
The European Commission has authorised Keytruda plus Padcev before and after surgery for adults with resectable muscle-invasive bladder cancer, expanding perioperative treatment options in the EU.

nuaxia
Oct 222 min read
bottom of page